Posts Tagged ‘monoclonal antibodies (MAb)’

Global Reach to the New website http://www.newmedinc.com – Oncology KnowledgeBASE and Future Oncology Newsletter

Posted in CANCER BIOLOGY & Innovations in Cancer Therapy, tagged biomarker/companion diagnostics, Immunotherapy, monoclonal antibodies (MAb), oligonucleotides and small molecule drugs, Oncology molecular targets on March 25, 2016| Leave a Comment »

Global Reach to the New website http://www.newmedinc.com – Oncology KnowledgeBASE and Future Oncology Newsletter

Reporter: Aviva Lev-Ari, PhD, RN

ANNOUNCEMENT

Image SOURCE: Google Images

New Access to and Global Reach Availability to the New website

http://www.newmedinc.com

UPDATED on 10/12/2016

To contact New Medicine, request a no-obligation 2-week access to nm|OK or to order nm|OK, please visit http://www.newmedinc.com.

Oncology Drug Development and Personalized Medicine Knowledgebase

Comprehensive resource covering all aspects of the global oncology sector
Detailed profiles of 5,000 new drugs in development and approved drugs worldwide
Detailed profiles of 2,250 companies worldwide developing and marketing therapeutic/in vivo imaging agents and/or in vitro diagnostics
Over 1,180 molecular markers identified as diagnostic and treatment targets
Thousands of affiliations/licensing agreements/spin-offs involving commercial entities and most major institutions worldwide

LAKE FOREST, Calif., April 12, 2016 /PRNewswire/ — New Medicine (http://www.newmedinc.com) has launched New Medicine’s Oncology KnowledgeBASE (http://www.nmok.net), a highly disciplined relational database that provides a comprehensive view of the global oncology sector.

nm|OK New Drugs and Marketed Drugs profiles
nm|OK provides detailed profiles of over 5,000 distinct drugs/in vivo imaging agents in development and on the market by:

developer/affiliate (over 1,000 pipelines)
generic name/brand name/other designation
technology/class
mechanism of action
cancer indications; over 100 indications
clinical indications; hundreds of indications
administration route
molecular target
biomarker/companion diagnostics
delivery technology
preclinical development status
clinical development by phase and status
clinical history, including trial protocols, interim and final results
sales history (when available)

Sample New Drug record
Sample Marketed Drug record

nm|OK Company profiles
nm|OK profiles over 2,250 companies in the oncology space in terms of:

history
management
financing
enabling technologies
affiliations/collaborations/licenses
pipelines, etc.

Sample Company records

nm|OK Targets in Oncology profiles
nm|OK profiles over 1,000 molecular targets implicated in cancer and its treatment in terms of:

cancer indication
utility (treatment, in vivo imaging, in vitro diagnosis, prognosis, disease monitoring, etc.
institution

Sample Target record

To contact New Medicine, request a no-obligation 2-week access to nm|OK or to order nm|OK, please visit http://www.newmedinc.com.

Past descriptions:

Oncology KnowledgeBASE and
Future Oncology Newsletter

Oncology KnowledgeBASE

New Medicine’s Oncology KnowledgeBASE (nm|OK) provides a comprehensive view of the status of the global oncology drug development and personalized medicine sector in terms of:

companies developing and marketing therapeutic/in vivo imaging agents and/or in vitro diagnostics
institutions/non-profits with affiliations/agreements in this sector
therapeutic agents in development or on the market globally (over 4,500 drugs in development)
molecular targets of approved drugs and of those currently evaluated in preclinical/clinical trials or identified as playing a role in cancer
patents, orphan drug status, sales, etc.

Sample Company records >
Sample New Drug record >
Sample Marketed Drug Record >
Sample Target Record >

Quarterly Updates >

Nm|OK New Drugs and Marketed Drugs profiles >

nm|OK provides detailed profiles of over 5,000 distinct drugs/in vivo imaging agents in development and on the market by

developer/affiliate (over 1,000 pipelines)
generic name/brand name/other designation
technology/class
mechanism of action
cancer indications; over 100 indications
clinical indications; hundreds of indications
administration route
molecular target
biomarker/companion diagnostics
delivery technology
development status
clinical development by phase and status
clinical history, including trial protocols, interim and final results
sales history (when available)

nm|OK Company profiles >

nm|OK profiles over 2500 companies in the oncology space in terms of

history
management
financing
enabling technologies
affiliations/collaborations/licenses
pipelines, etc.

nm|OK Targets in Oncology Profiles >

nm|OK profiles over 1,000 molecular targets implicated in cancer and its treatment in terms of

cancer indication
utility (treatment, in vivo imaging, in vitro diagnosis, prognosis, disease monitoring
institution

News and Special Reports

Future Oncology

Free_Icon From June 1995 to August 2008, New Medicine published Future Oncology, a comprehensive analytical newsletter tracking the evolution of global drug development in oncology. Despite of the incredible amount of effort in this area in the last 20 years, we currently face the same problems that were being tackled then, namely a lack of understanding as to the origins and mechanisms of malignancy. Despite the incredible global effort in this area and the remarkable scientific breakthroughs in biology and medicine, advanced cancer has remained an incurable disease. However, although cancer remains undefeated, treatment of this disease has created a huge global market comprised of drugs that, with few exceptions, provide marginal relief at a very high cost. Because the origins of this disease have remained obscure, there have been numerous approaches popularized at different times as to its treatment. Future Oncology has tracked these developments over time, from the rise of immunotherapy in the late 1990s to the subsequent discovery of oncogenes and tumor suppressors that shifted the emphasis from the labor intensive immunotherapy and gene transfer approaches to the relative simplicity of the production and delivery of monoclonal antibodies (MAb), oligonucleotides and small molecule drugs. Although some major advances have led to significant survival gains of patients with hematologic malignancies, they have not produced the same results in the treatment of metastatic solid tumors.

In the meantime, the competitive landscape underwent a major transformation. The archives follow the progress or demise of hundreds of commercial entities globally and hundreds of drugs, among some of the most successful to date as well some noted failures. The passage of time has produced many surprising winners and a few unexpected losers. Celgene, an unknown small company in 1995, has become a leading biotech juggernaut. Rituximab, a relatively low tech transformational therapy for the treatment of hematologic malignancies, developed by the small company Idec and approved in the USA in November 1997, may be considered the most successful anticancer agent to date both for significantly extending survival and for generating billions in sales for its developers and marketers. Since its first approval in 1995, Rituxan’s total global revenues exceeded $65 billion, including sales in the immunology sector beginning in FY 2013. Imatinib, launched in 2001, ushered the era of personalized medicine. Avastin, the first targeted treatment for solid tumors launched by Genentech in 2004, garnered over $60 billion in global revenues to date.